Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AM Rx vs Push Health

AM Rx
Graded #490

Lower grade

vs+6.300000000000004
Push Health
Graded #419

Higher grade

The verdict

Push Health takes it — 56.2/100 to 49.9/100.

Push Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Push Health is a large US telehealth platform that routes brand-name GLP-1 prescriptions (Ozempic, Zepbound, Mounjaro) through a 55,000+ pharmacy network.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAM Rx +16
51
35
Dose & formulationEven
65
65
Clinical oversightPush Health +30
41
71
Labs & monitoringPush Health +3
49
52
FulfillmentPush Health +9
58
67
Contract termsPush Health +35
20
55
AM Rx · left barPush Health · right bar

The numbers

MetricAM RxPush Health
WeighScore49.9/10056.2/100
GradeCC
Scorecard rank#490#419
Semaglutide$151/mo (quarterly plan, plus a separate fee, compounded)$950/mo (brand-name)
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
AM Rx

Graded #490 · C

Strengths

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

Where it loses points

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Push Health

Graded #419 · C

Strengths

  • Brand-name-only GLP-1 distribution (Ozempic, Zepbound, Mounjaro)
  • 55,000+ pharmacy network per competitor sources
  • LegitScript certified per competitor sources
  • Listed in both competitor directories

Where it loses points

  • Brand-name-only — no compounded option
  • Stub entry — exact pricing, insurance coordination, and clinician workflow need YMYL verification
  • Confidence LOW until verified

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard